To cite this paper use one of the standards below:
Glioblastoma (GBM) remains one of the most aggressive brain tumors, with limited therapeutic options and poor patient prognosis. Graphene oxide (GO)-based drug delivery systems have emerged as a promising strategy to overcome these challenges. Owing to its high surface area, amphiphilic nature, and versatile surface chemistry, GO enables efficient drug loading while maintaining favorable biocompatibility and physicochemical properties. Building on these advantages, GO-based supramolecular complexes were engineered to co-deliver temozolomide (TMZ), the standard-of-care chemotherapeutic agent for GBM, and AZD1390 (AZD), a novel brain-penetrant inhibitor of Ataxia-Telangiectasia Mutated (ATM) kinase, within a single nanocarrier. We hypothesize that this combinatorial approach may enhance antitumor efficacy by coupling TMZ-induced DNA damage with AZD-mediated inhibition of ATM-dependent DNA repair, thereby sensitizing GBM cells to treatment.
With nearly 200,000 papers published, Galoá empowers scholars to share and discover cutting-edge research through our streamlined and accessible academic publishing platform.
Learn more about our products:
This proceedings is identified by a DOI , for use in citations or bibliographic references. Attention: this is not a DOI for the paper and as such cannot be used in Lattes to identify a particular work.
Check the link "How to cite" in the paper's page, to see how to properly cite the paper